Treatment Result of Pediatric Osteosarcoma with Intraarterial Cisplatin.
- Author:
Hyoung Soo CHOI
1
;
Hyoung Jin KANG
;
Jun Ah LEE
;
Hyo Heong HAN
;
Hyeon Jin PARK
;
Eun Sun YOO
;
Woo Sun KIM
;
Hee Young SHIN
;
In One KIM
;
Sang Hoon LEE
;
Hyo Seop AHN
;
Han Koo LEE
Author Information
1. Department of Pediatrics, National University College of Medicine, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Osteosarcoma;
Intraarterial cisplatin;
Survival rate
- MeSH:
Amputation;
Chemotherapy, Adjuvant;
Cisplatin*;
Diagnosis;
Disease-Free Survival;
Doxorubicin;
Drug Therapy;
Extremities;
Follow-Up Studies;
Humans;
Limb Salvage;
Neoplasm Metastasis;
Osteosarcoma*;
Recurrence;
Seoul;
Survival Rate
- From:Journal of the Korean Cancer Association
1998;30(1):169-177
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: This study was performed to determine the outcome after treatment of osteosarcoma with intraarterial cisplatin as a preoperative chematherapy regimen. MATERIALS AND METHODS: Twenty five patients with extremity osteosarcoma were treated with intraarterial cisplatin at Seoul National University Children's Hospital from January 1987 to April 1996. The dose of cisplatin was 130 mg/m2 and three to six courses were repeated two- to three-week intervals, Systemic doxorubicin was added to six of these patients. This was followed by surgical resection(limb salvage or amputation) and postoperative adjuvant chemotherapy. RESULTS: Limb-salvage was possible in twenty of these twenty five patients. Pulmonary metastasis was present in five patients at diagnosis and developed later in three patients. In six patients treated with systemic doxorubicin, pulmonary metastasis was absent at diagnosis and during follow-up period. Local recurrence after limb salvage was occurred in one patient and treated with amputation and systemic chemotherapy. Seven patients died from pulmonary metastssis and one from unknown cause. The follow-up duration of these patients was three to eighty eight months(median twenty two months) and the overall five-year survival and event free survival rate were 62.1% and 57.5%, respectively. CONCLUSION: These data demonstrate that intraarterial cisplatin can be used as an effective regimen preoperatively for pediatric patients with extremity osteosarcoma. The combined use of systemic doxorubicin is expected to improve survival in patients with pulmonary metastasis.
